Iterum Therapeutics PLC (ITRM) — SEC Filings
Iterum Therapeutics PLC (ITRM) — 50 SEC filings. Latest: 8-K (Mar 31, 2026). Includes 31 8-K, 5 10-Q, 5 DEFA14A.
View Iterum Therapeutics PLC on SEC EDGAR
Overview
Iterum Therapeutics PLC (ITRM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: Iterum Therapeutics plc reported a net loss of $8.979 million for the three months ended September 30, 2025, an increase from a net loss of $6.094 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $20.379 million, up from $18.192 million in 2024. The
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 6 bearish, 44 neutral. The dominant filing sentiment for Iterum Therapeutics PLC is neutral.
Filing Type Overview
Iterum Therapeutics PLC (ITRM) has filed 31 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G, 1 SC 13G/A, 5 DEFA14A, 2 S-1/A, 1 S-1 with the SEC between Mar 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of ITRM's 46 recent filings, 5 were flagged as high-risk, 23 as medium-risk, and 18 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $390,000 |
| Net Income | -$8,979,000 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $11,002,000 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- PEO
- Non-PEO Neo Member
- Corey N. Fishman
- Dr. Corey Fishman
Industry Context
Iterum Therapeutics operates in the highly competitive pharmaceutical industry, focusing on developing and commercializing therapeutics. The market for antibiotics, particularly for resistant infections, is growing but faces challenges from existing treatments and the high cost of drug development and commercialization.
Top Tags
sec-filing (7) · regulatory-filing (6) · corporate-governance (6) · delisting (6) · pharmaceuticals (6) · 8-k (4) · financials (4) · 8-K (4) · 10-Q (4) · proxy-statement (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and Cash Equivalents | $11.0M | Decreased from $24.1M at Dec 31, 2024, raising going concern doubts. |
| Product Revenue, Net | $390K | First revenue generated from ORLYNVAH launch, but insufficient to cover costs. |
| Net Loss (Q3 2025) | $8.98M | Increased from $6.09M in Q3 2024, indicating worsening profitability. |
| Net Loss (YTD Sep 2025) | $20.38M | Increased from $18.19M in YTD Sep 2024, showing continued losses. |
| Selling, General & Administrative Expenses (Q3 2025) | $6.49M | Significantly increased from $1.78M in Q3 2024 due to commercialization. |
| Ordinary Shares Outstanding | 52,787,679 | As of November 13, 2025, indicating potential for further dilution. |
| Net Cash Used in Operating Activities (YTD Sep 2025) | $15.26M | High cash burn rate, contributing to going concern risk. |
| Cash and Cash Equivalents (Dec 31, 2024) | $24.13M | Significant decrease to $11.0M by Sep 30, 2025. |
| Start of equity award adjustment period | 2022-01-01 | Indicates the earliest year for which equity award adjustments are detailed for PEOs and Non-PEO Neo Members. |
| End of equity award adjustment period | 2024-12-31 | Represents the latest year for which equity award adjustments are detailed, showing ongoing compensation practices. |
| SEC File Number | 001-38503 | Unique identifier for Iterum Therapeutics' filings with the SEC. |
| Film Number | 251156859 | Internal SEC processing number for the filing. |
| Upfront Payment | $10.0M | Received from the sale of Iterum Therapeutics Ireland Limited. |
| Closing Period | Q3 2025 | Expected timeframe for the completion of the subsidiary sale. |
| Reporting Period End Date | 20250331 | Indicates the end of the financial quarter being reported. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Iterum Therapeutics PLC (ITRM)?
Iterum Therapeutics PLC has 50 recent SEC filings from Mar 2024 to Mar 2026, including 31 8-K, 5 10-Q, 5 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ITRM filings?
Across 50 filings, the sentiment breakdown is: 6 bearish, 44 neutral. The dominant sentiment is neutral.
Where can I find Iterum Therapeutics PLC SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Iterum Therapeutics PLC (ITRM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Iterum Therapeutics PLC?
Key financial highlights from Iterum Therapeutics PLC's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ITRM?
The investment thesis for ITRM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Iterum Therapeutics PLC?
Key executives identified across Iterum Therapeutics PLC's filings include PEO, Non-PEO Neo Member, Corey N. Fishman, Dr. Corey Fishman.
What are the main risk factors for Iterum Therapeutics PLC stock?
Of ITRM's 46 assessed filings, 5 were flagged high-risk, 23 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Iterum Therapeutics PLC?
Forward guidance and predictions for Iterum Therapeutics PLC are extracted from SEC filings as they are enriched.